We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| N4 Pharma Plc | N4P | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.40 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 11/6/2025 15:55 by earwacks Everything is way overdue with N4p. In particular Nigel’s resignation |
Posted at 20/3/2025 08:43 by pwal About time for some news N4P! |
Posted at 12/3/2025 12:52 by pwal Whether it's this week or next, N4P is expecting approval. |
Posted at 06/3/2025 12:20 by sharesoc If you missed this Webinar the recording is now available!Hear from SEEEN plc (SEEN) and N4 Pharma PLC (N4P) as they discuss their latest developments and future outlook. If you couldn’t attend live, this is your chance to catch up. Watch here: |
Posted at 10/2/2025 11:42 by sharesoc Discovery Company Webinar – 25 February, 5pmShareSoc, in collaboration with InvestorHub, presents the next Discovery Company Webinar, featuring: * N4 Pharma PLC (N4P) * SEEEN plc (SEEN) Hear from the CEOs of both companies as they provide insights into their current progress and future plans. Register here: |
Posted at 23/11/2024 09:37 by pwal Tweet:The @humancellatlas is transforming our understanding of health and disease. With newly uncovered cell types, including those linked to inflammation in #IBD, advanced therapies targeting specific cells such as Nuvec®, will be more in demand: bbc.co.uk/news/artic |
Posted at 11/11/2024 13:49 by pwal Who thinks N4P can hit 1p before the end of the year? |
Posted at 25/10/2024 13:28 by fido People should take a look at the PDF.In it the company clearly states that the upside from here is 20-50 times which would value N4P at more than 100 million. |
Posted at 24/10/2024 09:35 by pwal Well I guess now is the time to stock up on N4P. But it will be a slow burner.The Company's aim is to advance preclinical studies and prepare for a Clinical Trial Authorisation ("CTA") / Investigational New Drug ("IND") filing in the coming years |
Posted at 10/10/2024 08:08 by pwal Come on N4P! |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
